Innovative combination Finasteride + Tadalafil

Products

Information

Innovative combination Finasteride + Tadalafil Both products individually are approved for BPH (Benign prostatic hyperplasia) in Europe. The most frequent adverse reactions are impotence and decreased libido in Finasteride. The benefit of Tadalafil is early onset of therapeutic effect and reduction of finasteride-induced adverse events (e.g. erectile dysfunction) Co-administration of Tadalafil 5 mg and finasteride 5 mg is recommended by European association of Urology (EAU - Guideline for Management of Non-neurogenic Male LUTS) and approved by FDA for BPH for up to 26 weeks For more details contact Vaibhav Sharma, Head of Value added products (Vaibhav.Sharma@zentiva.com )
Main Categories
Finished Dosage Forms
All Categories
Finished Dosage FormsTablets
Distribution areas
AfricaEast Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
ZENTIVA / ZENT2U PRAGUE SCIENTIFICZentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites - including flagship sites in Prague, Bucharest and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people's daily healthcare needs. At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high quality affordable medicines and healthcare.

Log in

See all the content and easy-to-use features by logging in or registering!